Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828083 | 0.88 | POLB (0.43) | POLBSMN1; SMN2LMNAATMNPC1 | |
| SCHEMBL4830144 | 0.82 | PDE4A (0.51) | LMNA | |
| SCHEMBL14193556 | 0.74 | SMN1; SMN2 (0.54) | POLBSMN1; SMN2LMNAATMNPC1 | |
| SCHEMBL4830170 | 0.74 | POLB (0.54) | POLBSMN1; SMN2LMNAATMNPC1 | |
| SCHEMBL4825914 | 0.72 | POLB (0.44) | POLBSMN1; SMN2LMNAATMNPC1 | |
| SCHEMBL4831852 | 0.70 | ATM (0.42) | POLBSMN1; SMN2LMNAATMNPC1 | |
| SCHEMBL4830151 | 0.70 | PDE2A (0.41) | POLBSMN1; SMN2LMNANPC1KMT2A | |
| SCHEMBL7370389 | 0.70 | PDE4A (0.54) | LMNAKMT2A | |
| SCHEMBL4828112 | 0.69 | PDE4A (0.53) | LMNA | |
| SCHEMBL4830104 | 0.69 | PDE4A (0.51) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PDE4B, PDE4A, NOX4 | POLB 2221/4885SMN1; SMN2 1930/4885LMNA 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.